New England Research Institutes Release: TOPCAT Study Shows Spironolactone Did Not Reduce Serious Cardiovascular Events
4/11/2014 8:14:14 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the inexpensive medication known as spironolactone to existing treatment does not significantly reduce the composite outcome from either death from cardiovascular causes, sudden cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction, in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.
Help employers find you! Check out all the jobs and post your resume.
comments powered by